To the Editor.—
In response to the short report by Pavlidakey et al1 in the Archives, we, too, were intrigued by the proposal of Finzi et al2 that the underlying defect in pityriasis rubra pilaris (PRP) might be a deficiency of retinol binding protein, resulting in inadequate transport of vitamin A to the skin. Their success in treating three patients with stanozolol,3 an anabolic steroid used to elevate the levels of retinol binding protein, was also of great interest. Our experience in using stanozolol in the treatment of PRP, however, has been less encouraging.In an attempt to duplicate the results of Finzi et al, we gathered a series of five patients with classic adult PRP, diagnosed on clinical grounds with supportive histopathology. As in the case reported by Pavlidakey et al, baseline retinol binding protein levels were within the normal range. Nevertheless, we proceeded with a
Brice SL, Spencer SK. Stanozolol in the Treatment of Pityriasis Rubra Pilaris. Arch Dermatol. 1985;121(9):1105–1106. doi:10.1001/archderm.1985.01660090019004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: